solute carrier family 22 member 16Genealiases: CT2 · FLIPT2 · HEL-S-18 · OAT6 · OCT6 · OKB1
Q-omics provides the consensus-scored SLC22A16 profile across patient tissues and cancer cell-line models. SLC22A16 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, SLC22A16 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, SLC22A16 RNA expression shows 12,797 significant gene co-expression associations, with the highest sampling consensus in SKCM. Together, these results highlight STAD, KIRC, and SKCM as cancer lineages where SLC22A16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC22A16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC22A16 survival associations across molecular data types. SLC22A16 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC22A16 RNA expression–survival associations across cancer types. High SLC22A16 expression shows unfavorable associations in STAD, COAD, UCEC and KICH, but favorable associations in UCS and LAML. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for SLC22A16 RNA expression.
This table summarizes SLC22A16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC22A16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC22A16 shows lower tumor expression in KICH and higher tumor expression in KIRC, STAD, THCA, LIHC and PRAD. The KIRC box plot shows higher SLC22A16 RNA expression in tumor versus normal tissue (log2 FC = +0.286, t-test p < 0.001).
This table shows molecular features associated with SLC22A16 in patient tissues and cancer cell lines. In patient samples, SLC22A16 shows the broadest associations at the RNA and protein expression levels, with SKCM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC22A16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
